

MICROBIOTIX, INC., AWARDED OVER \$5 MILLION DEPARTMENT OF DEFENSE CONTRACT FOR THE DEVELOPMENT OF NOVEL BROAD-SPECTRUM ANTI-BACTERIALS.

Microbiotix*, Worcester, Mass., was awarded on Aug. 2, 2006, a \$5,064,555 cost-plus-fixed-fee contract for development of a novel broad-spectrum anti-bacterials for intracellular biological warfare threats. Work will be performed in Worcester, Mass. (44.3 percent), Fort Detrick, Md. (44.1 percent), and Alberta, Canada (11.6 percent), and is expected to be completed by Aug. 2, 2008. Contract funds will not expire at the end of the current fiscal year. There were an unknown number of bids solicited via the World Wide Web on Oct. 31, 2005, and 130 bids were received. The Defense Threat Reduction Agency, Fort Belvoir, Va., is the contracting activity (HDTRA1-06-C-0042).

About MicroBiotiX

Founded in 1998, MicroBiotiX, Inc. is a product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. MicroBiotiX currently has in development MBX 500, the first antibiotic that targets the DNA polymerase of Gram-positive bacteria, including drug resistant strains. The company further has an active research program to discover a broad-spectrum antibiotic that targets the DNA polymerase of drug-resistant Gram-positive and Gram-negative bacteria. Additionally, MicroBiotiX has an active biodefense program, focused on novel therapeutics for Bacillus Anthracis and Burkholderia pseudomallei, and is also actively involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance. More information can be found on the company's web site, www.MicroBiotiX.com.

* Small Business